Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Items 301–400 of 486
Pazos, J. V. G., Castro, J. D. O. E., Moysés, R. P. C., Lopes, F. N. B., & Ferreira, B. D. O. (2023) · Saúde e Pesquisa · doi:10.17765/2176-9206.2023v16n2.e11707 · Cited by 8
Expert opinion in mental disorder: Why is acceptance of the COVID-19 vaccines so problematic?
Gorman, J. M., Scales, D. A., & Gorman, S. E. (2021) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2021.100072 · Cited by 5
“Some insist that letting everyone get infected will establish so-called “ natural ” immunity and in this way accomplish community immunity, but a recent study of the situation in Manaus, Brazil, shows that this is not an option [5].”
COVID-19 and immunity: quo vadis?
Miyasaka, M. (2021) · International Immunology · doi:10.1093/intimm/dxab008 · Cited by 6
“[70] reported that the cumulative incidence of SARS-CoV-2 infection had reached ~75% by October 2020, exceeding any of the putative herd immunity threshold so far calculated.”
BackgroundLanzavecchia, S., Beyer, K. J., & Bolo, S. E. (2021) · Epidemiologia · doi:10.3390/epidemiologia2030028 · Cited by 5
“The emergence of new variants, especially the P1, the so-called Brazilian variant, first discovered in Manaus in November 2020 [31], seems to play an important role in Chile’s surge in new cases, according to S.”
BackgroundEstimating SARS-CoV-2 seroprevalence
Rosin, S. P., Shook‐Sa, B. E., Cole, S. R., & Hudgens, M. G. (2023) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1093/jrsssa/qnad068 · Cited by 9
Variantes do vírus SARS-COV-2 causadoras da COVID-19 no Brasil
Benito, L. A. O., Lima, R. D. C., Palmeira, A. M. D. L., Karnikowski, M. G. D. O., & da Silva, I. C. R. (2021) · Revista de Divulgação Científica Sena Aires · doi:10.36239/revisa.v10.n1.p205a219 · Cited by 11
Lata, S., & Akif, M. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30276 · Cited by 5
Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail
Campbell, C., Roblin, D. W., Padmanabhan, N., Romero, D., Joe, J., Fathi, L., Whiting, T., Williamson, J. N., Goodwin, P., Mckie, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17057-7 · Cited by 6
Ojal, J., Brand, S. P. C., Were, V. O., Okiro, E. A., Kombe, I. K., Mburu, C., Aziza, R., Ogero, M. O., Agweyu, A., Warimwe, G. M., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16748.3 · Cited by 18
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 20211
Justman, J. E., Skalland, T., Moore, A. T., Amos, C. I., Marzinke, M. A., Zangeneh, S. Z., Kelley, C. F., Singer, R. M., Mayer, S., Hirsch‐Moverman, Y., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3002.230863 · Cited by 5
“Serologic testing may have underestimated seroprevalence because of either absent or low titers after a mild infection ( 30 ) or waning antibody titers after a distant (>6 months) infection ( 31 ).”
BackgroundManaças, L. R. A., de Amorim, R. L. O., Aguila, A., Novo, P., & Badin, R. C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297490 · Cited by 6
Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020
Bogogiannidou, Z., Speletas, M. G., Vontas, A., Nikoulis, D. J., Dadouli, K., Kyritsi, M. A., Mouchtouri, V. Α., Mina, P., Anagnostopoulos, L., Koureas, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9050504 · Cited by 6
“The halflife of anti-SARS-CoV-2 antibodies has been calculated as 106 days [7] and, subsequently, several of them end in “serosilent” infections.”
BackgroundHajj-Hassan, H., Hamze, K., Abdel‐Sater, F., Kizilbash, N., & Khachfe, H. M. (2021) · Cureus · doi:10.7759/cureus.16905 · Cited by 5
“The spike protein is 1,273 amino acids long with two important functional regions: the N-terminal region (S1) (amino acids (aa) 14-682) responsible for viral attachment to target cells via the angiotensin-converting enzyme 2 (ACE2) receptor, and the C-terminal region (S2) (aa 686-1273) responsible for membrane fusion…”
BackgroundBackcasting COVID-19: a physics-informed estimate for early case incidence
Kevrekidis, G. A., Rapti, Z., Drossinos, Y., Kevrekidis, P. G., Barmann, M. A., Chen, Q. Y., & Cuevas–Maraver, J. (2022) · Royal Society Open Science · doi:10.1098/rsos.220329 · Cited by 7
“In sharp contrast, the lack of coordination at the federal level and delays in the implementation of mitigation measures in Brazil have been well documented [48,49].”
BackgroundVaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approachPreprint
VILCHES, T. N., Rubio, F. A., Perroni, R. A. F., de Almeida, G. B., Fortaleza, C. M. C. B., & Ferreira, C. P. (2021) · medRxiv · doi:10.1101/2021.02.22.21252208 · Cited by 5
“[37] have scrutinized, through donated blood samples, the attack rate in Manaus and São Paulo, two of the most dramatic examples of the rapid spread of COVID-19 in Brazil [37].”
BackgroundTherapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2Preprint
Ryu, D.-K., Kang, B., Woo, S., Lee, M., Tijsma, A. S. L., Noh, H., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.08.451696 · Cited by 6
A case series of SARS-CoV-2 reinfections caused by the variant of concern Gamma in BrazilPreprint
Naveca, F. G., do Nascimento, V. A., Nascimento, F., Ogrzewalska, M., Pauvolid‐Corrêa, A., de Araújo, M. F., Arantes, I., Batista, É. L. R., Magalhães, A. L. Á., Vinhal, F. A., et al. (2021) · medRxiv · doi:10.1101/2021.11.29.21266109 · Cited by 5
Self-citationEpidemiological and antigenic inferences from serological cross-reactivity among arboviruses
O’Driscoll, M., Hozé, N., Lefrancq, N., Santos, G. R. D., Hoinard, D., Rahman, M. Z., Paul, K. K., Naser, A. M., Alam, M. S., Hossain, M. E., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads8680 · Cited by 10
Viana, K. F., Zarpelon, L. F. B., Leandro, A., Terêncio, M. L., Lopes, R. D., Martins, C. A., Silva, I., Sibim, A. C., Marques, F., SILVA, R. D., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001684 · Cited by 4
Borges, L. P., Guimarães, A. G., Fonseca, D. L. M., Freire, P. P., Barreto, Í. D. D. C., de Souza, D. R. V., Gurgel, R. Q., Lopes, A. D. S. A., Neto, J. M. D. R., dos Santos, K. A., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11368 · Cited by 4
“For example, since schools reopened in Brazil when the community transmission was still at high levels, our data suggest that students and school workers may have been exposed before they returned to school [41].”
Self-citationA novel queue-based stochastic epidemic model with adaptive stabilising control
Arruda, E. F., Alexandre, R. E. A., Fragoso, M. D., do Val, J. B. R., & Thomas, S. S. (2023) · ISA Transactions · doi:10.1016/j.isatra.2023.06.018 · Cited by 6
“Consider, for instance, the state of Amazonas, Brazil: a largely unmitigated epidemic event whereby a serological study estimated an accumulated incidence of 76% [30, 31] in October 2020.”
Landim, M. G., Carneiro, M. L. B., Joanitti, G. A., Anflor, C. T. M., Marinho, D. D., Rodrigues, J. F. B., de Sousa, W. J. B., Fernandes, D. D. O., Souza, B. F., Ombredane, A. S., et al. (2023) · Discover Nano · doi:10.1186/s11671-023-03892-8 · Cited by 5
“Notwithstanding, SUS has faced challenges such as the scarcity of personal protective equipment (PPE), medicines, oxygen supplies, diagnostic testing for SARS-CoV-2, as well as the saturation of hospitals and collapse of the health system [1, 4, 5].”
BackgroundMethodStrength and weakness of disease-induced herd immunity in networks
Hiraoka, T., Ghadiri, Z., Rizi, A. K., Kivelä, M., & Saramäki, J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421460122 · Cited by 7
Peter, J. (2021) · South African Medical Journal · doi:10.7196/samj.2021.v111i4.15576 · Cited by 5
“[1] Mass vaccination with effective and safe vaccines is therefore undoubtedly the best option for all countries, including South Africa (SA), to minimise the health, economic and social tragedies of this pandemic.”
BackgroundPillai, S. S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.001 · Cited by 4
Tuli, H. S., Sak, K., Aggarwal, P., Iqubal, A., Upadhaya, S. K., Kaur, J., Kaur, G., & Aggarwal, D. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.763687 · Cited by 4
“Similarly, the Gamma variant (P.1)was emerged in theAmazon city ofManaus inDecember 2020 and has led to a surge in cases in Brazil (Buss et al., 2021).”
BackgroundInfluentialIndividualized Medicine in Africa: Bringing the Practice Into the Realms of Population Heterogeneity
Hussein, A. A., Hamad, R., Newport, M. J., & Ibrahim, M. E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.853969 · Cited by 5
“Environmental triggers are themselves subject to compatibility with molecular targets which are in turn under influence of allele frequency changes which vary between individuals and population to create a situation of unusual patterns of transmission and epidemicity, where even herd immunity, a central tenet in the c…”
BackgroundViala, V. L., Slavov, S. N., de Lima, L. P. O., Lima, A. R. J., Ribeiro, G. D. C., Martins, A. J., Petry, B., Banho, C. Á., Barros, C. R. D. S., Moncau, C. T., et al. (2022) · Viruses · doi:10.3390/v14071481 · Cited by 4
Chen, Y., Yang, M., Lai, J.-Z., Chen, J.-W., Wang, Y., Wei, S., Hou, S., Chen, C., & Wu, H.-S. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad614 · Cited by 4
“From the start of 2020 to mid-2020, the anti-SARS-CoV-2 prevalence rates among blood donors in Canada [22], the Netherlands [23], Kenya [24], and Brazil [25] were 0.7%, 5.9%, 8.0%, and 13.6%, respectively.”
BackgroundInfluentialFrom SARS to COVID-19: lessons we should have learned (but we did not)
Lopes, L. R., Campos, J. H. C., & Chaves, A. F. A. (2021) · Journal of Evidence-Based Healthcare · doi:10.17267/2675-021xevidence.2021.e3837 · Cited by 4
Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients
Silva-Junior, A. L., Oliveira, L. D. S., Belezia, N. C. T., Tarragô, A. M., Costa, A. G., & Malheiro, A. (2023) · Immuno · doi:10.3390/immuno3010007 · Cited by 4
Self-citationLeys, Y. E., Nwokocha, M., Walker, J. P., Butterfield, T. R., Frater, V., Thompson, T. K., Anderson, M., Cloherty, G., & Anzinger, J. J. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-1128 · Cited by 5
“4 signal-to-cutoff [S/CO]) than the manufacturer’s instructions was used for the SARS-CoV-2 nucleocapsidspecific IgG assay to increase sensitivity, as described elsewhere.(7) All samples in our study were tested with all three assays.”
MethodHandel, A., Miller, J. C., Ge, Y., & Fung, I. C. (2023) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2023.203 · Cited by 18
The COVID-19 herd immunity threshold is not low: A re-analysis of European data from spring of 2020Preprint
Fox, S. J., Potu, P., Lachmann, M., Srinivasan, R., & Ancel, L. W. (2020) · medRxiv · doi:10.1101/2020.12.01.20242289 · Cited by 9
Mathematical modeling suggests pre-existing immunity to SARS-CoV-2Preprint
Carlsson, M., Hatem, G., & Söderberg‐Nauclér, C. (2021) · medRxiv · doi:10.1101/2021.04.21.21255782 · Cited by 4
“To be concrete, if a model has a suitable shape and predicts Twave correctly, but gives C19tot = 90% whereas measured sero-prevalence indicates 52% [13], this could indicate that 42% are actually immune to infection, since 52 ≈ (1 − 0.”
BackgroundResultInfluentialMagalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2021) · medRxiv · doi:10.1101/2021.05.19.21257237 · Cited by 6
Raina, S., & Kumar, R. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1852_21 · Cited by 4
“Science suggested that the slowdown of COVID‐19 in the city of Manaus between May and October might have been due to the herd‐immunity achieved in the population due to the infections occurring in that area.[6] It was estimated that more than 60% of the population had been infected by June 2020; however, in”
BackgroundFinch, E., Nilles, E. J., Paulino, C. T., Skewes-Ramm, R., Lau, C. L., Lowe, R., & Kucharski, A. J. (2023) · medRxiv · doi:10.1101/2023.10.05.23296586 · Cited by 4
“In contrast, SARS-CoV-2 transmission was largely unmitigated in some settings such as in Manaus, Brazil, where 76% of the population are thought to have been infected by October 2020 (4).”
ResultOh, D., Hölzer, M., Börnigen, D., Paraskevopoulou, S., Duwe, S. C., Budt, M., Kerber, R., Mikołajewska, A., Böttcher, S., Seifried, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01093-1 · Cited by 5
“Notably, the Gamma wave of Manaus occurred in a setting of 76% seroprevalence, indicating that most citizens had beeninfectedpreviously,namelyduringthe fi rstCOVID-19wavethathad spread practically unmitigated through the capital 303 .”
Seabra, D. B. M. H., Oliveira, G. R. D. S., Silva, R., & Freitas, R. F. (2024) · Revista Brasileira de Educação Médica · doi:10.1590/1981-5271v48.3-2023-0292.ing · Cited by 4
“The city of Manaus faced unique challenges, including a shortage of medical resources and a high rate of virus transmission 31,32 .”
BackgroundAlzabeedi, K. H., Makhlof, R. T. M., Bakri, R. A., Ewis, A. A., Alhamdi, H. W. S., Habeebullah, T. M., Khogeer, A., Mulla, E. A. A., Roshan, S. A. M., Qabbani, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10081279 · Cited by 4
“Higher COVID-19 seroprevalences were also reported reaching 22.6–23% in Italy [38,39], 22.7% in New York City [40], 31.6% and 38% among HCWs in two different studies in Madrid, Spain [41,42], 44% in the Brazilian Amazon [43], and 65% among 60 seniors in Germany [44].”
BackgroundInfluentialEmergence of COVID-19 Variants and Its Global Impact
Kunal, S., Ish, P., Aditi, & Gupta, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_9 · Cited by 3
Aderinto, N., & Olatunji, G. D. (2023) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000137 · Cited by 4
“Microbiome analysis involves the study of microbial communities residing in various environments, including the human body([5]).”
BackgroundEvaluation of the Pan American Health Organization Response to COVID-19 2020-2022. Volume II Annexes
Pan American Health Organization (2023) · Pan American Health Organization eBooks · doi:10.37774/9789275127476 · Cited by 8
Raja, D., Dhanalakshmi, R., Jency, P. J., Srividya, A., Balakrishnan, V., & Kumar, A. (2023) · BMC Public Health · doi:10.1186/s12889-023-17095-4 · Cited by 5
“It concluded that mere exposure to natural infection will not aid in pandemic mitigation due to the existence of a robust neutralizing antibody response post-infection [20].”
BackgroundUpper bounds on overshoot in SIR models with nonlinear incidence
Nguyen, M. (2024) · npj Complexity · doi:10.1038/s44260-024-00010-2 · Cited by 9
Tess, B. H., Martelli, C. M. T., Alves, M. C. G. P., Cortés, F., Bernal, R. T. I., de Souza, W. V., Luna, E. J. D. A., Rodrigues, L. D. C., Nunes, M. C., Reinach, F. D. C., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309441 · Cited by 4
“The prevalence rate was higher in the Amazon than in S ã o Paulo (13.6%, 95% CI: 12.0– 18.1) in the same period, showing distinct patterns of the epidemic within the country [29].”
BackgroundInfluentialde Oliveira-Filho, E. F., Martínez-Vega, R. A., Moreira‐Soto, A., Beuchel, C., Freyle-Román, I. K., Mora‐Guevara, E., Rincón‐Orozco, B., & Drexler, J. F. (2024) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2024.102772 · Cited by 3
Miliu, A., Lavergne, A., Succo, T., Laizé, C., Andrieu, A., Enfissi, A., Enouf, V., van der Werf, S., Blanchet, D., Demar, M., et al. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105370 · Cited by 3
“Real-world data from Manaus confirmed immune evasion capacities for Gamma, estimating that 16.5% of infections in this first gamma regional epidemic were re-infections (Prete et al., 2021; Buss et al., 2021).”
InfluentialRobust trend estimation for COVID-19 in Brazil
Valente, F., & Laurini, M. P. (2021) · Spatial and Spatio-temporal Epidemiology · doi:10.1016/j.sste.2021.100455 · Cited by 3
Variations from SARS-CoV-2 to Omicron: A new threat knocking at world's door
Balkrishna, A., Rohela, A., Kumar, A., Arya, A., & Khan, N. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120404 · Cited by 3
Friston, K. J., Costello, A. M. D. L., Flandin, G., & Razi, A. (2021) · medRxiv · doi:10.1101/2021.01.03.20248972 · Cited by 3
Attack rate and the price of SARS-CoV-2 herd immunity in BrazilPreprint
Filho, T. M. R., Mendes, J. F. F., Chow, C. C., Phillips, J. C., Cordeiro, A., Scorza, F. A., de Almeida, A.-C. G., & Moret, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-659187/v2 · Cited by 3
What is the evidence in favor of herd immunity for the COVID-19 pandemics?
Chaves, A. F. A. (2021) · Journal of Evidence-Based Healthcare · doi:10.17267/2675-021xevidence.v2i2.3335 · Cited by 3
Rodríguez, M., Porras-Villamil, J. F., Martín, L. V., Rivera‐Monroy, J. E., Mantilla, Y. C., & Olivera, M. J. (2022) · New Microbes and New Infections · doi:10.1016/j.nmni.2022.101026 · Cited by 3
“0%) [3] and Buenos Aires, Argentina, (53.”
Telenfermagem: Implementação das Teleconsultas em um Hospital Universitário
Freitas, L. D. F. N., Jacinto, A. K. D. L., & Fernandes, J. M. A. (2024) · Research Society and Development · doi:10.33448/rsd-v13i3.45454 · Cited by 2
Quee, F. A., Hogema, B. M., Molier, M., Slot, E., van den Hurk, K., & Zaaijer, H. L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305613 · Cited by 2
Ferrante, L., Capanema, E., Steinmetz, W. A. C., Nelson, B., Almeida, A. C. L., Leão, J., Pereira, L. S., Vassão, R. C., Fearnside, P. M., & Tupinambás, U. (2024) · Journal of Public Health Policy · doi:10.1057/s41271-024-00530-0 · Cited by 2
Torgerson, P. R., Hartnack, S., Rasmussen, P., Lewis, F. I., O’Donnell, P. J., & Langton, T. (2025) · Royal Society Open Science · doi:10.1098/rsos.241609 · Cited by 2
“Epidemiological theory demands that analyses should include the diagnostic error of the test [9], for example, modelling the COVID-19 pandemic [10].”
Wei, H., Musa, S. S., Zhao, Y., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031729 · Cited by 3
España, G., Cucunubá, Z. M., Díaz, H., Cavany, S., Castañeda-Arias, N., & Rodriguez, L. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000467 · Cited by 5
“Under an assumption of no public health interventions, we observed a large outbreak with a peak of around 600 deaths per day, and an attack rate close to 75%, which was similar to attack rates observed in unmitigated outbreaks in South America [33].”
ResultBrinkworth, J. F., & Rusen, R. M. (2022) · Annual Review of Anthropology · doi:10.1146/annurev-anthro-041420-100047 · Cited by 3
Rejoinder: Regression Models for Understanding COVID-19 Epidemic Dynamics With Incomplete Data
Quick, C., Dey, R., & Lin, X. (2021) · Journal of the American Statistical Association · doi:10.1080/01621459.2021.2001340 · Cited by 2
Categorizing the Status of COVID-19 Outbreaks Around the WorldPreprint
Callan, J. P., Nouwen, C. J. A., Lexmond, A. S., & Fourtassi, O. (2021) · medRxiv · doi:10.1101/2021.03.08.21252586 · Cited by 2
Epidemic trends of SARS-CoV-2 modulated by economic activity, ethnicity, and vaccinationPreprint
Kamikubo, Y., & Takahashi, A. (2021) · doi:10.33774/coe-2021-xfgln · Cited by 2
Severity of SARS-CoV-2 reinfections in second wave determines likelihood of mild endemicityPreprint
Lavine, J. S., Bjørnstad, O. N., Coombs, D., & Antia, R. (2021) · medRxiv · doi:10.1101/2021.07.21.21260944 · Cited by 2
“We simulate from these equations with a basic reproduction number, R0 = 3 (the high end of the R0 estimated during wave 1 in Manaus) [1] from May 1 - Nov 6, the date on which the P.”
BackgroundMethodInfluentialHigh Infection to SARS-CoV-2 in an Indigen Community of the Colombian Amazon RegionPreprint
Coll, H. A. S., Miller, H., der hamen, C. R.-V., Gastelbondo, B., Novoa, W., Oviedo, M., Rivero, R., Garay, E., & Mattar, S., V (2021) · Preprints.org · doi:10.20944/preprints202109.0307.v1 · Cited by 2
Coccia, M. (2021) · Research Square · doi:10.21203/rs.3.rs-941879/v1 · Cited by 2
“…of an evolutionary growth of pandemic wave, it moves forward the optimal threshold between countries from about 59 to 86 doses of vaccines per 100 people to trigger the reduction of the transmission dynamics of COVID-19 (Buss et al., 2021; ECDC, 2021; Mallapaty, 2021; Whittaker et al., 2021).”
BackgroundThe impact of school reopening on COVID-19 dynamics in Bogotá, ColombiaPreprint
España, G., Cucunubá, Z. M., Díaz, H., Cavany, S., Castañeda-Arias, N., & Rodriguez, L. (2021) · doi:10.31219/osf.io/ebjx9 · Cited by 2
Kittikraisak, W., Hunsawong, T., Punjasamanvong, S., Wongrapee, T., Suttha, P., Piyaraj, P., Leepiyasakulchai, C., Tanathitikorn, C., Yoocharoen, P., Jones, A. R., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3990107 · Cited by 2
Key Considerations: Indigenous Peoples in COVID-19 Response and Recovery
Araujo, S. A., Cannon, M., Schmidt-Sane, M. M., Shankland, A., Snijder, M., & Wu, Y.-C. (2021) · OpenDocs (Institute of Development Studies) · doi:10.19088/sshap.2021.024 · Cited by 3
Attack rate and the price of SARS-CoV-2 herd immunity in BrazilPreprint
Filho, T. M. R., Mendes, J. F. F., Chow, C. C., Phillips, J. C., Cordeiro, A., Scorza, F. A., de Almeida, A.-C. G., & Moret, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-659187/v1 · Cited by 2
Arantes, I., Bello, G., Nascimento, V., Souza, V., da Silva, A. V., Silva, D., Nascimento, F., Mejía, M., Brandão, M. J., Gonçalves, L., et al. (2022) · medRxiv · doi:10.1101/2022.09.21.22280193 · Cited by 2
“(Buss et al., 2021; He et al., 2021a; Filho et al., 2021; Barber et al., 2022), and another fraction further received at least one dose of the SARS- CoV-2 vaccine (~50”
BackgroundSelf-citationLimitations of models for guiding policy in the COVID-19 pandemicPreprint
McKeigue, P., & Wood, S. N. (2022) · medRxiv · doi:10.1101/2022.06.30.22277091 · Cited by 2
“Seroprevalence rates 114 of more than 50% in the first wave have been reported only from the Amazonian region: 115 77% in blood donors in Manaus [15] in October 2020 and 70% in Iquitos in July 2020 116”
BackgroundInfluentialEpidemiological inferences from serological responses to cross-reacting pathogensPreprint
O’Driscoll, M., Hozé, N., Lefrancq, N., Santos, G. R. D., Hoinard, D., Rahman, M. Z., Paul, K. K., Titu, A. M. N., Alam, M. S., Hossain, M. E., et al. (2024) · medRxiv · doi:10.1101/2024.08.12.24311852 · Cited by 2
Fine, P., Mulholland, K., Scott, J. A. G., & Edmunds, W. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00078-5 · Cited by 1
Herd Immunity: Communicating Collective Action to Suppress COVID-19 in Two Nordic Countries
Mello, S. (2024) · Risk, systems and decisions · doi:10.1007/978-3-031-74062-6_26 · Cited by 1
Alexander, N. D. E., Dye, C., Busch, M. P., Buss, L., Junior, C. A. P., Brady, O. J., Mee, P., Abrahim, C. M. M., Crispim, M. A. E., Costa, A. G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0308319 · Cited by 1
Self-citationGil, D., Casas, R., Rufs, C., Valenzuela, E., & Undurraga, E. A. (2025) · Cities · doi:10.1016/j.cities.2025.106589 · Cited by 1
SARS‐CoV‐2 Detection and Persistence in a Remote Amazonian Settlement
da Silva, G. M., Ilacqua, R. C., Gonçalves, F. G., Santana, C. M., Jordão, F. T., Prist, P. R., Nolan, M. S., Brilhante, A. F., Sperança, M. A., & Laporta, G. Z. (2025) · Journal of Tropical Medicine · doi:10.1155/jotm/4872494 · Cited by 1
“In Bel´em (Par´a), seroprevalence reached 39% after the frst wave [24], and in Manaus (Amazonas), seroprevalence reached 76%, refecting a largely unmitigated epidemic with high mortality [25].”
Pearce, N. E., & Silva, T. C. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf197 · Cited by 1
Braeye, T., Abrams, S., & Hens, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0328144 · Cited by 1
Landoni, G., Faustini, C., Marmiere, M., R., G. C. S., Ruggeri, A., & Zangrillo, A. (2021) · Signa Vitae · doi:10.22514/sv.2021.149 · Cited by 1
“Immunoglobulins were detectable in 44%of the population inManaus [5] and in 42.”
BackgroundXu, J., Lim, A., & Rutherford, G. W. (2022) · Journal of Correctional Health Care · doi:10.1089/jchc.21.03.0024 · Cited by 1
“In one longitudinal study of antibody seroprevalence over the course of multiple months during an unmitigated epidemic in a major city in the Brazilian Amazon, sero-prevalence peaked at 52.5% roughly 2 months after the first case was identified in the city (Buss et al. , 2021).”
InfluentialFatores de virulência microbianos e terapias emergentes
Barbosa, A. V., da Silva, S. M., da Silva, F. H. S., de Assunção, M. A. S., & dos Anjos, F. B. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000093 · Cited by 2
Brazil and the (Un)Natural Selection of SARS-CoV-2
Machado, S. H. (2022) · Annals of Public Health Reports · doi:10.36959/856/532 · Cited by 1
Advances in Diagnosis and Treatment for SARS-CoV-2 Variants
Akhter, N., Sana, S., Ahsan, M. A., Siddique, Z., Huraira, A., & Sana, S. (2023) · Infectious diseases · doi:10.5772/intechopen.107846 · Cited by 1
COVID-19 in Brazil: Overall Impact and Singularities
de Macedo, A. V. (2023) · Springer eBooks · doi:10.1007/978-981-99-1106-6_24 · Cited by 1
de Oliveira, M. B. M., Manaças, L. R. A., & Badin, R. C. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e14684.2023 · Cited by 1
Quaresma, S. M. B., de Oliveira, M. B. M., Santana, I. B., Manaças, L. R. A., Pereira, V. N., & Badin, R. C. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e15960.2024 · Cited by 1
Madinga, J. N., Kingebeni, P. M., Nkuba-Ndaye, A., Baketana, L., Matungulu-Biyala, E., Lupola, P. M., Seghers, C.-A., Smekens, T., Ariën, K. K., Damme, W. V., et al. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00536-0 · Cited by 1
“Within cohorts, seroreversion of IgG has been demonstrated, which was close to 40% over a 5-month period in a study in the USA [10].”
BackgroundResultAn Analytic Look at the Last Pandemic’s Spread and Its Control by Decision-Makers
VILCHES, T. N., Rubio, F. A., de Almeida, G. B., & Ferreira, C. P. (2024) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-3-031-56794-0_5 · Cited by 1
Our choice is not binary between lockdown and herd immunity
Cheng, K. K. (2020) · BMJ · doi:10.1136/bmj.m4051 · Cited by 1
Dhuria, M. (2020) · Epidemiology International · doi:10.24321/2455.7048.202027 · Cited by 1
Spitzer, M. (2021) · Nervenheilkunde · doi:10.1055/a-1298-1189 · Cited by 1
“[40] Buss LF, Prete CA Jr, Abrahim CMM et al.”
BackgroundFuchs, V. B. (2021) · International Journal of Social Quality · doi:10.3167/ijsq.2021.11010208 · Cited by 1
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants
Lebourgeois, S., Chenane, H. R., Houhou‐Fidouh, N., Menidjel, R., Ferré, V. M., Collin, G., Benmalek, N., Coppée, R., Larrouy, L., Yazdanpanah, Y., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.792202 · Cited by 1
“The Alpha variant, also known as the 20I/ gy | www.frontiersin.org December 2021 | Volume 11 | Article 7922021 501Y.V1 or B.1.1.7 variant, has been firstly detected in London in December 2020 and rapidly spreading across Europe and worldwide.”
BackgroundInfluentialImpact of the lethal "Politics" variant on the population in Brazil
da Silva, R. M. (2022) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2022.005 · Cited by 1
Narváez, P. E. C., & Castañeda-Orjuela, C. A. (2022) · Gerencia y Políticas de Salud · doi:10.11144/javeriana.rgps20.drvc · Cited by 2
Data-driven approach in a compartmental epidemic model to assess undocumented infections
Costa, G. S., Cota, W., & Ferreira, S. C. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112520 · Cited by 1
Self-citation
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.